The firms plan to use Thermo Fisher's Oncomine Dx Target test to identify cancer patients with RET alterations who might benefit from Lilly's LOXO-292.
NantHealth's net loss fell by 37 percent, to $14.7 million, as revenue from software-related revenue jumped by 23 percent while expenses fell.
During a conference call to discuss the firm's second-quarter results, CEO and President Francis deSouza also highlighted potential growth from clinical sequencing.
The embattled company saw its net loss narrow during the first quarter, in part due to a new policy of giving away fewer nonreimbursed GPS Cancer and Liquid GPS molecular test orders than in the past.
Research presented at ACMG by Invitae suggests that clinically actionable variants in cancer patients are missed by germline testing that is not done with expanded panels.
The firm anticipates that it will soon launch the device as an in vitro diagnostic tool for analyzing tissue biopsies during surgeries in European hospitals.
The company's net loss more than doubled in Q4 to $49.1 million.
The Navify software, which Roche launched today, provides annotation, interpretation, and clinical reporting of next-generation sequencing tests for cancer.
Singapore-based Lucence Diagnostics will team with Stanford to analyze sequencing and imaging of liver cancer patients to predict therapeutic effectiveness.
The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.